The Pharmacy Times® Diabetes resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Although hypoglycemia can be fatal, continuous glucose monitoring may reduce risk.
The rate of weight gain during pregnancy, use of insulin pumps, and CGMS have increased in women with type 1 diabetes, according to new research.
Researchers looked at the effects of a genetic risk score for developing T2D as an adult on metabolism, measured from blood samples taken from participants in the study when they were aged 8, 16, 18, and 25 years.
Being able to predict life expectancy will help care providers decide which A1c target ranges are the best for each patient with diabetes.
Visual impairment confers a tremendous psychosocial burden, yet up to half of atrisk patients skip annual eye examinations. symposium held in conjunction with the Asembia Specialty Pharmacy Summit, noting that up to 17% of cases of blindness can be attributed to diabetic eye disease.
Pharmacy Times spoke with Robert Schumm, MBA, president of Ascensia Diabetes Care, about the challenges that patients with diabetes are facing during the COVID-19 pandemic.
A phase 2 clinical trial demonstrated that a 2-week course of teplizumab was able to delay the onset of clinical type 1 diabetes by 3 years compared with patients taking a placebo.
Using artificial intelligence (AI) and automated monitoring, researchers and physicians at Oregon Health & Science University (OHSU) have designed a method to help people with type 1 diabetes better manage their glucose levels.
Ertugliflozin is a relatively new addition to the SGLT2 inhibitor class of medication.
According to a recent study presented at the ADA’s 80th Scientific Sessions, youth and young adults with type 1 diabetes (T1D) in the United States today have worse glycemic control than prior generations.
Anti-interleukin-21, Liraglutide Combination Treatment in Adults Results in Sustained Insulin Secretion, Lower Insulin Dose
Treatment of recently diagnosed patients with type 1 diabetes (T1D) with anti-IL-21 and liraglutide for 54 weeks was found to be safe and resulted in sustained insulin secretion and lower insulin dose.
Prevention Program Shows Persistent Reduction of Type 2 Diabetes Development Over 22-Year Average Follow-Up
The DPPOS is the long-term follow-up of the Diabetes Prevention Program (DPP), a multicenter trial conducted from 1996 to 2001 that established the success of either an intensive lifestyle program or treatment with metformin to prevent or delay the development of T2D in individuals who were considered at high risk for developing the disease.